Clinical trial · no report yet · Phase 2
IFm2022-01
Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma
- NCT06353022 ↗
- Active not recruiting
- Nantes University Hospital
- 5 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| X threads | 4 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma: A Phase 2 (IFM 2022-01)
- Phase
- Phase 2
- Status
- Active not recruiting
- Conditions
- Multiple Myeloma
- Interventions
- Teclistamab; Talquetamab; Lenalidomide; Bortezomib; Daratumumab; Dexamethasone
- Arms
- Teclistamab and Lenalidomide · Experimental
- Talquetamab andTeclistamab · Experimental
- Enrollment
- 103 (estimated)
- Primary outcomes
- Rate of sustained MRD negativity (NGS, 10^-5)
- Rate of conversion from positive MRD to negative MRD (NGS, 10^-5)
- Sponsor
- Nantes University Hospital with Janssen Pharmaceutica
- Start
- Jun 26, 2024
- Primary completion
- Apr 26, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT06353022 · updated Mar 17, 2026